Comments on: Trends Update — “Personalized Effectiveness”: Amgen Gets Prospective Data to Back KRAS-Vectibix Plan http://crossborderbiotech.ca/2009/08/11/trends-update-personalized-effectiveness-amgen-gets-prospective-data-to-back-kras-vectibix-plan/ Biotechnology, Health and Business in Canada, the United States and Worldwide Mon, 02 Apr 2012 12:31:04 +0000 hourly 1 http://wordpress.com/ By: Q3 Is Looking Up for Biotech: Emdeon, Cumberland, Domain, LOM BioQuest, OETF « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/08/11/trends-update-personalized-effectiveness-amgen-gets-prospective-data-to-back-kras-vectibix-plan/comment-page-1/#comment-808 Wed, 12 Aug 2009 21:49:19 +0000 http://crossborderbiotech.ca/?p=2860#comment-808 [...] personalized medicine seeing increasing validation as a clinical strategy, genomics is going to be increasingly prominent.  News this week from Helicos Biosciences that an [...]

]]>